Soleil Boughton Reports RSU Vesting and Tax Share Withholding at Hims & Hers on November 13, 2026
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., filed a Form 4 on November 17, 2026, detailing RSU vesting and tax-related share withholding transactions that occurred on November 13, 2026. Boughton acquired 42,262 Class A Common Stock shares through RSU settlements, with 21,500 shares withheld at $19.73 each to cover tax liabilities. After these transactions, Boughton's direct ownership stands at 314,648 shares, with an additional 281,205 RSUs beneficially owned.
eyeQ: Rightmove, Antofagasta, Barclays, Hims & Hers
eyeQ, using AI and its smart machine, generates actionable trading signals by analyzing share prices against its Model Value. This week's report highlights UK stocks like Antofagasta and Barclays as trading below their Model Value, implying they are "cheap," while Rightmove appears "rich." Internationally, Hims & Hers Health Inc is flagged as significantly undervalued based on macro conditions, triggering a bullish signal despite recent stock price falls.
(HIMS) Price Dynamics and Execution-Aware Positioning
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting a weak near and mid-term sentiment but a neutral long-term outlook. AI models have generated three distinct trading strategies: a long position trading strategy, a momentum breakout strategy, and a tactical short risk hedging strategy, each with specific entry, target, and stop loss levels. Key findings indicate an exceptional risk-reward setup targeting a 40.4% gain versus a 0.3% risk.
Hims & Hers Health Inc. Q3FY26 Results: Loss widens to $0.14, revenue up 49%
Hims & Hers Health Inc. reported a Q3FY26 loss of 14 cents per share, missing consensus estimates, despite a 49% year-on-year revenue increase to $890.373 million, which also fell short of projections. The company narrowed its FY26 revenue guidance and appointed neuroscientist Andrew Huberman to its board of directors. Following the report, several analysts lowered their price targets, reflecting caution on the company's valuation.
Hims & Hers Health, Inc. Reports Third Quarter 2026 Financial Results
Hims & Hers Health, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting approximately $890 million in revenue, a 49% increase year-over-year, and subscriber growth to nearly 2.8 million. The company also tightened its full-year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and adjusted its Adjusted EBITDA guidance to $257 million to $277 million. These results reflect continued strategic growth, particularly in international markets, and investments aimed at long-term expansion.
Hims & Hers Health short interest rises to 23% ahead of Q3 results
Short interest in Hims & Hers Health has increased to 23% as the company prepares to release its third-quarter results. Despite a 65% decline in stock price from its 2025 peak, analysts project a 49% year-over-year revenue increase to $892 million for Q3, supported by new partnerships with Eli Lilly for GLP-1 weight loss drugs. The high short interest also sets up potential for a short squeeze if earnings surpass expectations.
HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit
Rosen Law Firm reminds purchasers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, of the November 2, 2026, lead plaintiff deadline in a securities fraud lawsuit. The lawsuit alleges that Hims made materially false and misleading statements, including sharing consumer health information with third parties and charging for prescriptions before a consultation, which led to regulatory scrutiny and potential penalties. Investors who purchased Hims securities during this period may be entitled to compensation and are encouraged to contact the Rosen Law Firm to join the class action.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Hims (NYSE: HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
Faruqi & Faruqi, LLP is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) about the November 2, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Hims made false and misleading statements, including sharing sensitive health information with third parties and deceptive billing practices, which led to regulatory scrutiny from the Federal Trade Commission and a significant drop in Hims' stock price on July 29, 2026. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to contact the law firm to discuss their options.
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS),
The Law Offices of Frank R. Cruz reminds investors of upcoming lead plaintiff deadlines for securities class action lawsuits against Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA). Investors in these companies who suffered losses are encouraged to contact the law firm to learn about their legal rights and participate in the class actions, with a lead plaintiff motion deadline of November 2, 2026, for all three cases. The lawsuits allege false or misleading statements by the defendants regarding various aspects of their business operations and regulatory compliance.
HIMS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urges Hims & Hers Health, Inc. Investors to Contact the Firm Before November 2nd
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), alleging the company made false and misleading statements about its business practices, including sharing health information and charging consumers without prior consultations. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are urged to contact the firm before the November 2, 2026 deadline to apply as lead plaintiff. The lawsuit claims that Hims' actions could lead to regulatory scrutiny, fees, and penalties.
Hims & Hers Health 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS
Kahn Swick & Foti, LLC (KSF) is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) with losses over $100,000 that they have until November 2, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Hims & Hers Health and its executives failed to disclose material information regarding the sharing of sensitive health data and deceptive billing practices, which led to a significant drop in stock price after an FTC announcement on July 29, 2026. KSF is encouraging affected investors to contact them to discuss their legal rights and potential recovery.
What Should Hims & Hers Health, Inc. Investors Know After 14.73% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
The Law Offices of Frank R. Cruz has announced a class action lawsuit against Hims & Hers Health, Inc. following a 14.73% stock drop. The lawsuit alleges that the company made misleading statements to investors between August 4, 2025, and July 29, 2026, regarding deceptive privacy practices, including sharing sensitive health data, and misleading billing methods. Investors who acquired securities during this period and suffered losses have until November 2, 2026, to file a motion to serve as lead plaintiff.
HIMS 3-DAY DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Action
Hagens Berman is encouraging investors of Hims & Hers Health, Inc. (NYSE: HIMS) who suffered significant losses to contact the firm before the November 2, 2026, lead plaintiff deadline. This follows a securities class action lawsuit against the company and its executives, stemming from a federal complaint by the FTC accusing Hims of deceptive health data sharing, subscription billing violations, and other business misconduct. The lawsuit alleges Hims misled investors about its privacy policies and internal controls, leading to a substantial drop in stock price on July 29, 2026.
HIMS Deadline in 3 Days: Hims & Hers Health, Inc. (HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Hims & Hers Health, Inc. (HIMS) for investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that HIMS made misleading statements and failed to disclose unlawful privacy practices, including sharing consumer health information with third-party advertising platforms, leading to a stock price drop after the FTC filed a lawsuit. Investors have until November 2, 2026, to seek lead plaintiff status.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers made materially false and misleading statements regarding its practices, including sharing consumer health information with third parties, charging for prescriptions prematurely, and facing regulatory scrutiny, which ultimately exposed the company to potential fees and penalties. Investors who suffered losses are encouraged to join the case and may request to be appointed lead plaintiff by November 1, 2026.
Hims & Hers chief legal officer sells $95,551 in company stock
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 3,462 shares of the company’s Class A Common Stock for a total of $95,551 on October 28, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Ms. Boughton beneficially owns 293,886 shares of the company.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
A class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and its officers, alleging violations of federal securities laws. The lawsuit claims that Hims & Hers Health made false and misleading statements regarding sharing consumer health information with third-party advertising platforms, charging for prescriptions prematurely, and facing regulatory scrutiny. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging that the company made false and misleading statements to investors. The lawsuit claims Hims shared consumer health information with third-party advertising platforms and charged for prescriptions without proper medical consultation. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case by November 1, 2026.
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS
ClaimsFiler is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) with losses over $100,000 that the lead plaintiff deadline for a securities class action lawsuit is November 2, 2026. The lawsuit alleges that Hims & Hers and certain executives failed to disclose material information and violated federal securities laws, specifically regarding the sharing of sensitive health information with third-party advertisers and deceptive billing/cancellation practices, as revealed by an FTC lawsuit on July 29, 2026. This news caused Hims & Hers shares to drop significantly.
HIMS November 2, 2026 Lead Plaintiff Deadline - Robbins LLP
Robbins LLP reminds investors of the November 2, 2026 lead plaintiff deadline for a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). The lawsuit alleges that Hims shared consumers' sensitive health information with advertising platforms despite privacy claims and engaged in deceptive billing practices, leading to a significant stock drop after the FTC filed a lawsuit. Investors who suffered losses between August 4, 2025, and July 29, 2026, may be eligible to participate.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged securities fraud. The lawsuit claims the company made misleading statements by providing customer health data to third-party advertising platforms and that its practices were likely to draw regulatory scrutiny, causing investors to suffer losses. Shareholders who purchased HIMS stock between August 4, 2025, and July 29, 2026, have until November 2, 2026, to contact SBS regarding lead plaintiff appointments.
HIMS Deadline in 5 Days: Hims & Hers Health, Inc. Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is informing investors about a securities fraud class action lawsuit against Hims & Hers Health, Inc. (HIMS). The lawsuit alleges HIMS made materially false and misleading statements, specifically regarding the sharing of consumer health information with third-party advertising platforms and deceptive prescription practices. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead plaintiff status.
Kaplan Fox Advises Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Contact the Firm Before the Deadline on November 2, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit follows an FTC action alleging that Hims & Hers failed to disclose immediate prescription charges, made subscription cancellations difficult, and shared consumer health information with third parties. Investors have until November 2, 2026, to move the court to become lead plaintiff.
Investors in York Space, Hims & Hers, Unicycive, and Papa John's face lead plaintiff deadlines in securities fraud cases.
The Law Offices of Frank R. Cruz is reminding investors in York Space Systems, Hims & Hers Health, Unicycive Therapeutics, and Papa John's International of upcoming deadlines to seek lead plaintiff status in securities fraud class actions. These lawsuits allege that the companies made false or misleading statements that impacted their stock values. Investors who suffered losses during the specified class periods need to file motions by late October or early November 2026 to participate.
Hims & Hers Health, Inc. (NYSE:HIMS) SHAREHOLDER ALERT:
The Portnoy Law Firm has filed a securities class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased stock between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers misleadingly shared consumers' health information with third-party advertising platforms and engaged in deceptive billing practices, which led to a Federal Trade Commission (FTC) lawsuit and a nearly 15% drop in stock price. Investors have until November 2, 2026, to seek appointment as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) and its officers, alleging federal securities law violations. The lawsuit claims Hims made false and misleading statements by sharing consumer health information with third parties, charging for prescriptions prematurely, and facing regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.
Weekly Recap: FDA & FTC scrutiny, margin strain and Zava buy expands UK reach
Hims & Hers Health (NYSE:HIMS) is navigating regulatory challenges in the U.S., including an FDA review of peptide rules and an FTC lawsuit concerning privacy and billing practices, while simultaneously expanding its European presence through the acquisition of London-based telehealth firm Zava. The company also launched Kyzatrex, an FDA-approved oral testosterone replacement therapy, and is addressing a consumer deception lawsuit by asserting that plaintiffs ignored disclosed terms. Despite these challenges, Hims & Hers is shifting sales towards branded products like Kyzatrex.
HIMS 1-WEEK DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Action
Hagens Berman is encouraging Hims & Hers Health (NYSE: HIMS) investors with substantial losses to contact them before the November 2, 2026 deadline in a securities class action lawsuit. The lawsuit alleges Hims & Hers Health engaged in deceptive health data sharing, violating the Restore Online Shoppers' Confidence Act (ROSCA) by enrolling consumers in recurring subscriptions without informed consent. This follows a federal complaint by the FTC, which led to a significant stock crash for Hims shares on July 29, 2026.
Deadline Alert: Hims & Hers Health, Inc. Investors Have
Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors in Hims & Hers Health, Inc., reminding them that they have until November 2, 2026, to seek a lead plaintiff role in a securities fraud class action lawsuit. The lawsuit alleges the company made materially false and misleading statements, specifically regarding the sharing of consumer health information with third-party advertisers and deceptive billing practices, which led to a significant drop in stock price following a federal complaint filed on July 29, 2026. Investors who purchased Hims & Hers securities between August 4, 2025, and July 29, 2026, are affected.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged securities fraud. The lawsuit claims Hims & Hers made false statements by providing customer health data to third-party advertising platforms, potentially leading to increased regulatory scrutiny. Shareholders who purchased HIMS shares between August 4, 2025, and July 29, 2026, are encouraged to contact SBS to discuss their rights and possible lead plaintiff appointments before the November 2, 2026, deadline.
HIMS Deadline in 7 Days: Hims & Hers Health, Inc. (NYSE: HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that HIMS engaged in deceptive and unlawful privacy practices by sharing consumers' health information with third-party advertising platforms and charging for prescriptions before a consultation. Investors have until November 2, 2026, to seek lead plaintiff status in the case, which follows a Federal Trade Commission lawsuit against HIMS.
INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline
Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers made misleading statements and failed to disclose that it shared consumers' health information with third-party advertisers and deceptively billed for prescriptions. Investors who suffered substantial losses have until November 2, 2026, to seek appointment as lead plaintiff.
HIMS Deadline: Rosen Law Firm Urges Hims & Hers Health, Inc. (NYSE: HIMS) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm is reminding investors about a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of securities purchasers between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers misled investors by sharing consumer health information with third parties, improperly charging for prescriptions, and failing to disclose regulatory scrutiny. Shareholders have until November 2, 2026, to file as a lead plaintiff in the case.
HIMS Deadline: Rosen Law Firm Urges Hims & Hers Health, Inc. (NYSE: HIMS) Stockholders to Contact the Firm for Information About Their Rights
The Rosen Law Firm is reminding investors about a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of purchasers of securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims made materially false and misleading statements, including sharing consumer health information with third-party advertisers and charging for prescriptions before medical consultations. Shareholders have until November 2, 2026, to file motions to serve as lead plaintiff.
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) with substantial losses that they have until November 2, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Hims & Hers failed to disclose material information and violated federal securities laws, stemming from a Federal Trade Commission (FTC) lawsuit claiming the company shared sensitive health information with third parties and deceived users about billing and cancellation practices. Following the FTC announcement, Hims & Hers shares dropped over 14%.
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is reminding investors with significant losses in Hims & Hers Health, Inc. that they have until November 2, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Hims & Hers Health and certain executives failed to disclose material information, violating federal securities laws, particularly regarding deceptive privacy and billing practices as highlighted by an FTC lawsuit. Following the FTC's announcement, Hims & Hers Health shares dropped over 14%.
HIMS INVESTOR NOTICE: RGRD Law Announces that Hims & Hers
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), urging investors with substantial losses to seek lead plaintiff status before November 2, 2026. The lawsuit alleges that Hims & Hers made false statements, shared sensitive health information with third-party advertisers, and engaged in deceptive billing practices, leading to a Federal Trade Commission lawsuit and a nearly 15% decline in Hims & Hers shares.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) and its officers. The lawsuit alleges that Hims made materially false and misleading statements, including sharing consumer health information with third parties and charging for prescriptions before medical consultations. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging that the company made materially false and misleading statements to investors. The lawsuit claims Hims shared consumer health information with third parties, charged for prescriptions prematurely, and failed to disclose regulatory scrutiny, leading to potential fees and penalties. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), alleging that the company made false and misleading statements to investors. The lawsuit claims Hims shared consumer health information with third-party advertisers and charged for prescriptions before medical consultations. Investors who purchased Hims securities between August 4, 2025, and July 29, 2026, are encouraged to join the case by November 1, 2026.
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS
ClaimsFiler is reminding investors who suffered losses exceeding $100,000 in Hims & Hers Health, Inc. (NYSE: HIMS) to file lead plaintiff applications by November 2, 2026, in a class action lawsuit. The lawsuit alleges that Hims & Hers and its executives failed to disclose material information and violated federal securities laws, specifically regarding allegations by the FTC about the company's handling of sensitive health information and deceptive billing practices. This news caused Hims & Hers shares to drop significantly on July 29, 2026.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Pomerantz LLP has filed a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), urging investors who suffered losses to contact the firm. The lawsuit follows a Federal Trade Commission complaint alleging that Hims & Hers shared sensitive health information with third-party advertisers and engaged in deceptive billing practices. As a result of this news, Hims & Hers' stock price fell significantly.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) for alleged securities fraud, stemming from the company's supposed practice of providing customer health data to third-party advertising platforms and the likelihood of increased regulatory scrutiny. Investors who purchased HIMS shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead plaintiff appointment in the lawsuit. SBS encourages affected shareholders to contact the firm to discuss their rights and participate in the case.
INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - HIMS
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS), urging investors who purchased securities between August 4, 2025, and July 29, 2026, and suffered substantial losses, to seek lead plaintiff status by November 2, 2026. The lawsuit alleges that Hims & Hers misled investors by sharing sensitive health information with third-party advertisers, charging for prescriptions prematurely, and engaging in deceptive billing practices, all of which led to regulatory scrutiny and a nearly 15% stock price decline following a Federal Trade Commission lawsuit announcement.
HIMS 12-DAY DEADLINE ALERT: Hims & Hers Health Faces Securities Fraud Class Action, Investors with Losses Encouraged to Contact Hagens Berman
Hims & Hers Health, Inc. (NYSE: HIMS) is facing a securities fraud class action lawsuit following a federal complaint by the FTC, which accuses the company of serious business misconduct including deceptive health data sharing and violating subscription billing laws. Investors who suffered substantial losses between August 4, 2025, and July 29, 2026, are encouraged to contact Hagens Berman, with a lead plaintiff deadline of November 2, 2026. The lawsuit focuses on Hims' alleged sharing of sensitive health information with third-party advertisers and improper recurring subscription practices.
Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm Before November 2, 2026, for Information About Leading the Lawsuit Against Hims & Hers Health, Inc.
Robbins LLP is reminding investors of Hims & Hers Health, Inc. (NYSE: HIMS) about a pending class action lawsuit. The lawsuit alleges that Hims shared consumers' sensitive health information with advertising platforms despite privacy claims and engaged in deceptive billing practices. Investors who suffered losses during the Class Period (August 4, 2025, to July 29, 2026) are encouraged to contact Robbins LLP before the November 2, 2026, lead plaintiff deadline.
Hims & Hers Health, Inc. Securities Fraud Class Action
Kahn Swick & Foti, LLC (KSF) reminds investors of Hims & Hers Health, Inc. (NYSE: HIMS) that they have until November 2, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Hims & Hers failed to disclose material information regarding deceptive privacy and billing practices, which led to a significant stock decline after the FTC announced a lawsuit against the company. The FTC alleges that the telehealth provider shared sensitive health information with third-party advertising platforms and deceived users about billing and cancellation policies.
Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, Inc. Investors of the Upcoming Lead Plaintiff Deadline and Urges Investors to Contact the Firm Before November 2nd
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS) on behalf of investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that Hims & Hers made false statements, including sharing health information with third parties, charging for prescriptions without proper consultation, and facing regulatory scrutiny. Investors have until November 2, 2026, to apply to be appointed as lead plaintiff.
What's Next for Hims & Hers Health, Inc. Shareholders After 14.73% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Glancy Prongay Wolke & Rotter LLP has announced a class action lawsuit against Hims & Hers Health, Inc. for investors who purchased securities between August 4, 2025, and July 29, 2026. The lawsuit alleges the company misled investors regarding privacy practices and billing after a 14.73% stock drop on July 29, 2026, due to a federal complaint filed against them. Investors have until November 2, 2026, to seek a lead plaintiff role in the case.
What's Next for Hims & Hers Health, Inc. Shareholders After 14.73% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Glancy Prongay Wolke & Rotter LLP announced a class action lawsuit against Hims & Hers Health, Inc. following a 14.73% stock drop due to a federal complaint alleging deceptive privacy and billing practices. Investors who purchased securities between August 4, 2025, and July 29, 2026, are covered by the lawsuit and have until November 2, 2026, to seek a lead plaintiff role. The complaint accuses Hims & Hers of sharing sensitive user health data and misleading consumers about consultations and subscription cancellations.